AssetMark Inc’s Tonix Pharmaceuticals TNXP Stock Holding History

AssetMark Inc’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$29	Hold	3	–	–	﹤0.01%	3739
2026 Q2	$38	Hold	3	–	–	﹤0.01%	3512
2026 Q1	$41	Hold	3	–	–	﹤0.01%	3406
2025 Q4	$47	Hold	3	–	–	﹤0.01%	3338
2025 Q3	$72	Hold	3	–	–	﹤0.01%	3138
2025 Q2	$108	Hold	3	–	–	﹤0.01%	2934
2025 Q1	$54	Buy	+3	New	+$61	﹤0.01%	2591

Other funds holding TNXP

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Acorn Wealth Advisors Grand Blanc, Michigan $407M AUM 14.44% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CNBT

Cornerstone National Bank & Trust Palatine, Illinois $309M AUM 7.69% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

AssetMark Inc's TNXP Position: Q3 2026 in Review

AssetMark Inc held its Tonix Pharmaceuticals (TNXP) position steady in Q3 2026 at 3 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

AssetMark Inc first reported a position in TNXP in Q1 2025 and has held it in 7 quarters since. The position peaked at $108 in Q2 2025. 16 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

AssetMark Inc held 3 shares of Tonix Pharmaceuticals worth $29 as of Q3 2026.
AssetMark Inc left its Tonix Pharmaceuticals share count unchanged in Q3 2026.
Tonix Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3739 holding.
AssetMark Inc first reported a position in Tonix Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
AssetMark Inc's Tonix Pharmaceuticals position peaked at $108 in Q2 2025.
16 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.